LIBX-A402 (Compound 15b) is a selective ACSL4 inhibitor with an IC50 of 0.33 µM. It notably safeguards MDA-MB-231 and LUHMES cells from ferroptosis. LIBX-A402 is applicable in research focused on cancer, ischemia-reperfusion injury, and neurodegenerative disorders such as Parkinsons disease.
Target-Kategorie:
Ferroptosis
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
